Market Place
Sourcing Support
Evolus Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
13 Dec 2024 //
BUSINESSWIRE
Evolus Reports Q3 2024 Results
06 Nov 2024 //
BUSINESSWIRE
Evolus Announces EU Approval of Estyme® Injectable Gel
31 Oct 2024 //
BUSINESSWIRE
Evolus Rewards™ Program Surpasses 1 Million Enrolled Consumers
29 Oct 2024 //
BUSINESSWIRE
Evolus Q3 Financial Results on November 6, 2024
23 Oct 2024 //
BUSINESSWIRE
Evolus Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
11 Oct 2024 //
BUSINESSWIRE
Evolus Reports Inducement Grants Under Nasdaq Listing Rule
27 Sep 2024 //
BUSINESSWIRE
Evolus To Ring Nasdaq Closing Bell On September 13, 2024
06 Sep 2024 //
BUSINESSWIRE
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Aug 2024 //
BUSINESSWIRE
Evolus to Hold Investor Day on September 12, 2024
31 Jul 2024 //
BUSINESSWIRE
Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance
31 Jul 2024 //
BUSINESSWIRE
Evolus Introduces Nuceiva® In Australia
30 Jul 2024 //
BUSINESSWIRE
Evolus Submits Premarket Approval Application to FDA for Evolysse Dermal Fillers
26 Jun 2024 //
PHARMABIZ
Evolus submits PMA application for Evolysse™ dermal filler products.
24 Jun 2024 //
BUSINESSWIRE
Evolus Launches Nuceiva In Spain Broadening International Presence
12 Jun 2024 //
BUSINESSWIRE
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2024 //
BUSINESSWIRE
Evolus Announces Positive Evolysse Filler Pivotal Trial Data
20 May 2024 //
BUSINESSWIRE
Evolus Celebrates 5 Years Of Jeuveau At WWD Beauty CEO Summit
15 May 2024 //
BUSINESSWIRE
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 May 2024 //
BUSINESSWIRE
Evolus Reports First Quarter 2024 Results and Provides Business Update
07 May 2024 //
BUSINESSWIRE
Evolus to Report First Quarter Financial Results on May 7, 2024
23 Apr 2024 //
BUSINESSWIRE
Evolus Inducement Grants Under Nasdaq 5635(c)(4)
12 Apr 2024 //
BUSINESSWIRE
Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference
26 Mar 2024 //
BUSINESSWIRE
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
11 Mar 2024 //
BUSINESSWIRE
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 Mar 2024 //
BUSINESSWIRE
Evolus Announces Results from European Head-to-Head Filler Trial
01 Mar 2024 //
BUSINESSWIRE
Evolus to Participate in Leerink Partners and Barclays Investor Conferences
27 Feb 2024 //
BUSINESSWIRE
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Feb 2024 //
BUSINESSWIRE
Evolus Announces Preliminary Fourth Quarter and Full-Year 2023 Net Revenue
16 Jan 2024 //
PRESS RELEASE
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12 Jan 2024 //
BUSINESSWIRE
Evolus Announces the Appointment of Nareg Sagherian to Vice President
04 Jan 2024 //
BUSINESSWIRE
Evolus Enters into Licensing Agreement with Symatese
20 Dec 2023 //
BUSINESSWIRE
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13 Nov 2023 //
BUSINESSWIRE
Evolus Reports Record Third Quarter 2023 Financial Results
07 Nov 2023 //
BUSINESSWIRE
Evolus to Participate in November Investor Conferences
01 Nov 2023 //
BUSINESSWIRE
Phase 2 Data Evaluating 40U Dose of PrabotulinumtoxinA-xvfs to be Presented
25 Oct 2023 //
BUSINESSWIRE
Evolus to Report Third Quarter 2023 Results
25 Oct 2023 //
BUSINESSWIRE
Evolus Announces Inducement Grants for New Chief Marketing Officer
23 Aug 2023 //
BUSINESSWIRE
Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer
21 Aug 2023 //
BUSINESSWIRE
Evolus hits go on Jeuveau rebrand to expand reach to all genders
10 Aug 2023 //
FIERCE PHARMA
Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing
08 Aug 2023 //
BUSINESSWIRE
Evolus puts on `youthful` new look for frown line treatment Jeuveau
08 Aug 2023 //
ENDPTS
Evolus Reports Second Quarter 2023 Results and Provides Business Update
02 Aug 2023 //
BUSINESSWIRE
Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue
27 Jul 2023 //
BUSINESSWIRE
Evolus to Participate in Canaccord Genuity’s 43rd Annual Growth Conference
26 Jul 2023 //
BUSINESSWIRE
Evolus Reports First Quarter 2023 Results and Provides Business Update
09 May 2023 //
BUSINESSWIRE
Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™
09 May 2023 //
BUSINESSWIRE
Evolus to Report First Quarter 2023 Results and Provide Business Update
05 May 2023 //
BUSINESSWIRE
Evolus Reports Fourth Quarter and Full Year 2022 Results
08 Mar 2023 //
BUSINESSWIRE
Evolus to Participate in the Barclays Global Healthcare Conference
28 Feb 2023 //
BUSINESSWIRE
Evolus Initiates Nuceiva® Launch in Germany and Austria
27 Feb 2023 //
BUSINESSWIRE
Evolus to Report Fourth Quarter and Year End 2022 Results
22 Feb 2023 //
BUSINESSWIRE
Evolus Not Affected by Recent Korean Court Ruling
10 Feb 2023 //
BUSINESSWIRE
Evolus to Participate in the SVB Securities Global Biopharma Conference
31 Jan 2023 //
BUSINESSWIRE
"Extra-Strength" Formulation of Jeuveau Demonstrates Effects in PII Data Results
28 Jan 2023 //
BUSINESSWIRE
Evolus to Present Phase 2 Interim Data from Jeuveau “Extra-Strength” Dose
23 Jan 2023 //
BUSINESSWIRE
Evolus Receives Regulatory Approval for Nuceiva® in Australia
23 Jan 2023 //
BUSINESSWIRE
Evolus Announces Preliminary Unaudited Q4 and Full-Year 2022 Net Revenue
18 Jan 2023 //
BUSINESSWIRE
Evolus Extends Term of Credit Facility with Pharmakon Advisors
08 Dec 2022 //
BUSINESSWIRE
Evolus Reports Third Quarter 2022 Results and Provides Business Update
08 Nov 2022 //
BUSINESSWIRE
